MTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex by M. Pema et al.
ARTICLE
Received 30 Jul 2015 | Accepted 20 Jan 2016 | Published 2 Mar 2016
mTORC1-mediated inhibition of polycystin-1
expression drives renal cyst formation in tuberous
sclerosis complex
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Previous studies report a cross-talk between the polycystic kidney disease (PKD) and
tuberous sclerosis complex (TSC) genes. mTOR signalling is upregulated in PKD and
rapamycin slows cyst expansion, whereas renal inactivation of the Tsc genes causes cysts.
Here we identify a new interplay between the PKD and TSC genes, with important
implications for the pathophysiology of both diseases. Kidney-speciﬁc inactivation of either
Pkd1 or Tsc1 using an identical Cre (KspCre) results in aggressive or very mild PKD,
respectively. Unexpectedly, we ﬁnd that mTORC1 negatively regulates the biogenesis of
polycystin-1 (PC-1) and trafﬁcking of the PC-1/2 complex to cilia. Genetic interaction studies
reveal an important role for PC-1 downregulation by mTORC1 in the cystogenesis of
Tsc1 mutants. Our data potentially explain the severe renal manifestations of the TSC/PKD
contiguous gene syndrome and open new perspectives for the use of mTOR inhibitors in
autosomal dominant PKD caused by hypomorphic or missense PKD1 mutations.
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A
utosomal dominant polycystic kidney disease (ADPKD) is
a common genetic disorder characterized by massive
bilateral renal cyst formation1. Two genes are associated
with the disease: PKD1 mutated in 85% of cases and PKD2
mutated in the remaining 15% (refs 1,2). ADPKD is a chronic
condition characterized by the continuous formation and
expansion of cysts arising from the epithelia lining the tubules
of a minority of nephrons, which gradually causes compression
and loss of function of all nephrons within a kidney. End stage
kidney disease requiring renal replacement therapies ensue
in 50% of affected individuals before age 60 (ref. 1). Intense
studies in the past decade have lead to the identiﬁcation of
numerous signalling pathways that appear to be de-regulated in
the cystic epithelia1,2. Several of these pathways and cascades have
been considered potential good targets for therapy, irrespective of
whether or not their defective regulation causes cyst formation or
is caused by cyst formation3. Pathways that have been proposed
to be de-regulated in PKD include Caþ þ homoeostasis, cAMP
upregulation, MAPK, mTOR and STAT signalling, sirtuins and
TNF1,2. Prominent defective metabolic rates have also been
described in ADPKD animal models, providing additional
opportunities for therapy3,4. Although these studies have
identiﬁed potential new targets for therapies, only one class
(vasopressin receptor 2 antagonists) has reached the stage of
approval for therapy in Japan, Canada and Europe5. Despite this
progress, the primary cause of cyst formation remains elusive3.
Dysregulation of the mTOR pathway in ADPKD has attracted
a great deal of attention both for the potential of using its
inhibitors (rapalogues) as potential therapies and for the
unusually intriguing cross-talk bewteen two genes mutated in
different genetic disorders6–10. Several studies have implicated
crosstalk between the PKD genes and the genes mutated in a
genetic disorder called tuberous sclerosis complex (TSC)6,7,9,10.
First, TSC patients can manifest with a variable degree of renal
cysts11. Second, TSC is caused by mutations in either the TSC1 or
the TSC2 genes and the proteins they encode are central
regulators of the mTOR pathway12,13, which is hyperactive in
some PKD mouse models and in some human cysts.
Furthermore, the PKD1 gene product polycystin-1 (PC-1),
inhibits the mTORC1 cascade8,9,14. Treatment with rapamycin
proved effective in retarding cyst growth in animal models of
PKD8,10,15, although subsequent human clinical trials generated
mostly negative results16–18. The possibility of cross-talk between
PKD and TSC was ﬁrst hypothesized on the basis of genetic
evidence. The PKD1 and TSC2 genes are positioned tail-to-tail on
the same chromosome, and large deletions causing disruption of
both genes frequently result in massive and precocious renal
cystic phenotypes in infants19. No mechanistic explanation has
been proposed for this phenotype but previous studies showed
that conditional inactivation of the Tsc genes in the mouse kidney
results in renal cystogenesis20–23.
In response to these studies, some investigators have
hypothesized that the mTOR pathway might play a more
proximal role in cyst formation because of the similarities in
the phenotype when the Pkd and the Tsc genes are inactivated
in the kidney21,22. However, a direct comparison between the
phenotype generated by inactivation of these two classes of genes
by using the same Cre line has not been reported. Here, we show
that inactivation of the Tsc1 gene using a kidney-speciﬁc Cre line
(Ksp:Cre) results in a much milder phenotype than inactivation
of the Pkd1 gene using the same Cre line. These data per se might
suggest that mTOR is only one of the several pathways
de-regulated by inactivation of the Pkd1 gene and therefore the
phenotype is not entirely recapitulated. In search for additional
explanations for this difference in the phenotype, we
unexpectedly found that the mTORC1 cascade regulates the
expression of PC-1. Importantly, using genetic interaction studies
we found that re-expression of Pkd1 in the Tsc1-mutant
kidneys corrects the phenotype. Our data show that TSC-PKD
cross-talk is more complex than expected and that
downregulation of the PKD1 gene product might play an
important role in cyst formation in TSC.
Results
Different time of mTORC1 upregulation and renal cystogenesis.
To better understand cross-talk between the TSC and PKD genes
in renal cyst formation, we intercrossed mice harbouring either
Pkd1 (ref. 24) or Tsc1 (ref. 25) ﬂoxable alleles with an identical Cre
line (KspCre)26, which is active in the distal tubules and collecting
ducts starting at E14.5, both on the same genetic background
(C57Bl/6). Pkd1ﬂox/ﬂox:KspCre mice manifest a fast and aggressive
renal cystic phenotype causing death of the animals by P12 as
previously reported (Fig. 1a,b)4,27. Biochemical analysis revealed
that phosphorylation of S6K, a target of mTORC1, is increased in
these kidneys at P4 when cysts are already visible (Fig. 1c).
By contrast, Tsc1ﬂox/ﬂox:KspCre mice are born with normal
kidneys. At P10, Tsc1ﬂox/ﬂox:KspCre mice show increased
phosphorylation of S6K, showing upregulation of mTORC1
biochemically as expected (Fig. 1d and Supplementary Fig. 1a,b),
but no evidence of renal cysts, except for a few tubular dilatations
(Fig. 1e,f). Similar results were generated when comparing
Pkd1ﬂox/-:KspCre with Tsc1ﬂox/-:KspCre mice (Supplementary
Fig. 1c-f). Notably, at P20 Tsc1ﬂox/ﬂox:KspCre mice have an
enhanced kidney/body weight, which is present in a high
proportion of samples analysed (Fig. 1g), while cyst formation
can be observed in only B20% of the animals (Fig. 1h). As
previously reported, the appearance of the epithelia lining the cysts
is morphologically different in Pkd1 versus Tsc1 mutant kidneys,
with the ﬁrst being characterized by a ﬂat epithelium and the
second by a columnar epithelium (Supplementary Fig. 1g).
Analysis of proliferation using Ki67 as a marker for all cell-cycle
phases revealed that upregulation of proliferation can be observed
both in the cystic and in the non-cystic samples (o15%, Fig. 1i,j).
These data indicate that increased proliferation alone does not
seem to be sufﬁcient to drive cystogenesis, similarly to what
recently proposed28, although it is sufﬁcient to cause kidney
enlargement. Importantly, these data taken together show that
there is a time-disconnect between mTORC1 upregulation and
cyst formation. Thus, mTORC1 upregulation is not per se sufﬁcient
to recapitulate renal cystogenesis in Pkd1 mutants, in line with the
raising idea that alterations in a single pathway alone are not
sufﬁcient to recapitulate the cystic phenotype.
mTORC1 downregulates PC-1 expression levels. We next aimed
at studying the TSC/PKD cross-talk using mouse embryonic
ﬁbroblasts (MEFs) derived from Tsc1 / embryos29. Using an
antibody directed against PC-1, we unexpectedly observed a
downregulation of PC-1 expression levels in Tsc1 mutant as
compared with control WT cells (Fig. 2a). Rapamycin restored
the expression levels of PC-1 (Fig. 2b,c) in a time and
dose-dependent manner (Fig. 2c, and Supplementary Fig. 2a,b),
suggesting that mTORC1 can regulate PC-1 expression levels.
Pkd1 wild-type mouse embryonic ﬁbroblasts derived from
different litters in different labs, all responded to rapamycin
treatment by upregulating PC-1 expression levels (Supplementary
Fig. 2a,b). Furthermore, a different inhibitor of mTOR, Torin1
(300 nM), also restored PC-1 expression levels in Tsc1 mutant
cells and enhanced its expression in wild-type cells (Fig. 2d).
A second antibody directed against the C-terminal tail of
PC-1 (rCC)30 further conﬁrmed the downregulation of PC-1 in
Tsc1 / cells, but also in Tsc2mutant cell lines and in both cases
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rapamycin was able to restore normal expression levels (Fig. 2e,f).
Finally, we generated a set of murine inner medullary collecting
duct (mIMCD) cells carrying stable expression of shRNAs
directed against the Tsc1 gene. We achieved a 80% silencing
level leading to upregulation of mTORC1 as expected in two
stable transfectants as compared to scrambled transfected clones
(Supplementary Fig. 2d). In these cell lines, as well, we observed a
marked downregulation of PC-1 in cells carrying Tsc1 silencing as
compared with scrambled controls (Fig. 2g).
mTORC1 regulation of PC-1 requires protein neo-synthesis.
From the above studies we conclude that mTORC1 regulates
PC-1 expression levels and aimed at understanding how this
regulation occurs. Quantitative real time analysis revealed no
difference in the levels of Pkd1 messanger RNA present in
the Tsc1þ /þ and Tsc1 / cells, nor in the Tsc1 controls as
compared to the Tsc1ﬂoxﬂox:KspCre kidneys, suggesting that
downregulation does not occur at the transcriptional level
(Supplementary Fig. 3a,b). We next asked whether rapamycin
treatment might result in upregulation of the mRNA levels.
Indeed, long-term treatment (24 h) did result in upregulation of
the mRNA (Supplementary Fig. 3a,c). However, short-term
treatment (3 and 5 h) was able to upregulate the protein
levels (Fig. 3a), without affecting the mRNA levels (Fig. 3b).
Furthermore, treatment with rapamycin enhanced the expression
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Figure 1 | Inactivation of Pkd1 and Tsc1 leads to a different phenotype. (a) H&E staining of kidney sections from controls mice and Pkd1f/f:KspCre at P4
and P8. Scale bar, 1,000mm. (b) Graph shows the two kidneys weight over body weight ratio for controls and Pkd1f/f:KspCre mice analysed at P4 (controls
n¼4, cystic n¼ 3) and P8 (controls n¼ 5, cystic n¼4). Data are shown as mean±s.e.m. ANOVA statistical analysis (***Po0.0001) followed by
Bonferroni’s multiple comparison test was performed. ***Po0.001. (c) Representative western blot analysis of total kidney lysates from Pkd1f/f:KspCre mice
compared to control shows upregulation of the mTORC1 cascade at P4. (d) Western blot analysis of total lysates from P10 Tsc1f/f:KspCre and control
kidneys. Data are reperesentative of four independent experiments. (e) Representative H&E staining of kidney sections from Tsc1f/f:KspCre mice and
controls at P10 and P20. Scale bar, 1,000mm. (f) Immunoﬂuorescence on kidney sections from Pkd1 and Tsc1 mutants performed with markers of the
proximal (LTL, green) and distal tubules/collecting ducts (DBA, red). Scale bar, 45 mm. (g) Graph shows the two kidneys weight over body weight ratio in
Tsc1f/f:KspCre mice (n¼ 25) versus controls (n¼ 26). Data are shown as mean±s.e.m. Student’s unpaired two-tailed t-test was performed. ***Po0.001.
F test was performed to compare variances. (h) Graph shows the distribution of P20 Tsc1f/f:KspCre (n¼ 9) mice according to the percentage of cysts
affecting the kidneys. (i) Graph shows the percentage of Ki67 positive cells in controls (n¼ 3) and in Tsc1f/f:KspCre mice (cystso15% n¼ 6, cysts415%
n¼ 3) performed at P20. A minimum of 5,000 cells per sample was counted (1,500 cells per section in three different sections in each sample). Data are
shown as mean±s.e.m. ANOVA (***P¼0.0007) followed by Dunnett’s multiple comparison test was performed. **Po0.01, ***Po0.001. (j) Figure shows
immunohistochemistry for Ki67 proliferation marker performed on kidney sections from control and Tsc1f/f:KspCre mice at P20. Arrows evidence Ki67
positive nuclei. Scale bar, 50 and 100mm. ANOVA, analysis of variance.
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levels of PC-1 in two distinct sets of MDCK typeII cell lines stably
transfected with the cDNA of human PKD1 under the control of
a viral promoter (Fig. 3c,d)31. These data taken together suggest
that the regulation occurs primarily at the protein level, although
long-term treatment with rapamycin might also affect the levels
of transcript.
Next we asked if mTORC1 regulates PC-1 degradation levels.
Tsc1þ /þ and Tsc1 / MEFs were treated with Bortezomib
(75 nM) to inhibit proteasomal degradation and we observed no
effect on PC-1 expression levels in response to proteasomal
inhibition (Supplementary Fig. 3d). Next we treated with
Chloroquine (100 mM), which inhibits the lysosomes, the second
major protein degradation pathway in cells (Supplementary
Fig. 3e). This treatment did enhance PC-1 levels suggesting
that this receptor is degraded via the lysosomes, but did not
rescue the expression levels of PC-1 in Tsc1 / MEFs
(Supplementary Fig. 3e). Similar results were generated using
Baﬁlomycin to inhibit lysosomal degradation (Supplementary
Fig. 3f). We next examined if mTORC1 regulates PC-1
neo-synthesis. We inhibited protein neo-synthesis with 50 mM
cycloheximide in a time-course experiment both in Tsc1þ /þ and
Tsc1 / MEFs (Fig. 3e,f). Western blot analysis revealed that
after 6 h of cycloheximide treatment PC-1 expression is
approximately 50% of the total expression levels in both cell
lines, even if the degradation curves appear slightly different
within the ﬁrst few hours, further supporting the notion that
degradation rates are not different between control and Tsc1 /
cells (Fig. 3e,f). After 24 h of cycloheximide treatment PC-1
appears almost totally degraded both in Tsc1þ /þ and Tsc1 /
ﬁbroblasts (Fig. 3e,f). Notably, treatment of Tsc1þ /þ and Tsc1 /
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Figure 2 | mTORC1 regulates polycystin-1 expression levels. (a) Tsc1þ /þ and Tsc1 /ﬁbroblasts were immunoblotted for endogenous PC-1. Graph
shows quantiﬁcation of 12 independent experiments. Data are shown as mean±s.e.m. Statistical analysis was performed using the Student’s unpaired
two-tailed t-test. ***P¼0.0009. F-test was used to compare variances. *P¼0.0423. (b) Western blot analysis of PC-1 levels in Tsc1þ /þ and Tsc1 /
cells cultured with or without 100 nM rapamycin. Data are representative of ﬁve independent experiments. *shows a non-speciﬁc band. (c) Tsc1þ /þ
and Tsc1 /ﬁbroblasts treated with or without 50 nM rapamycin for 6, 24 and 48 h and immunoblot-detecting PC1. Data are representative of two
independent experiments. *shows a non-speciﬁc band. (d) Tsc1þ /þ and Tsc1 / cells treated with Torin1 300 nM followed by immunoblot of PC1.
(e) Immunoblot using an anti-C-terminal tail of PC-1 antibody (rCC)30 in Tsc1þ /þ and Tsc1 / cells before and after 100nM rapamycin. Arrows indicate
the speciﬁc bands, * shows a non-speciﬁc band. (f) Immunoblot using an anti-C-terminal tail of PC-1 antibody (rCC)30 in Tsc2þ /þ and Tsc2 / cells
before and after 100 nM rapamycin. Arrows indicate the speciﬁc bands, * shows a non-speciﬁc band. (g) Immunoblot using an anti-C-terminal tail of PC-1
antibody (rCC)30 or against the LRR repeats (7e12) in two distinct clones of mIMCD3 cells infected with a shRNA directed against the Tsc1 gene (shTSC1-1
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MEFs with rapamycin (100 nM) in the presence or absence of
50 mM cycloheximide shows that the latter completely counteracts
the rapamycin capability to enhance PC-1 expression levels
(Fig. 3g,h). In conclusion, our data collectively demonstrate that
mTORC1 activity negatively regulates the expression levels of PC-
1 through a process requiring protein neo-synthesis and point to
a possible role of mTORC1 in regulating Pkd1mRNA translation.
Rapamycin induces expression of mature functional PC-1 in cilia.
PC-1 is a very-large polypeptide, which undergoes a number of
post-translational modiﬁcations including glycosylation and
cleavage32–35. We therefore asked whether the different isoforms
of PC-1 might be differentially regulated by the mTORC1
pathway. As shown above, analysis of endogenous PC-1 using an
antibody directed against the C-terminal tail of the protein
revealed that both the uncleaved (FL-PC1) and the GPS-cleaved
isoforms of PC-1 (CTF, C-terminal fragment and NTF,
N-terminal fragment) are downregulated in Tsc1 / cells and
both isoforms are sensitive to rapamycin treatment (Fig. 2e).
Furthermore, treatment with rapamycin of MEFs carrying
Myc-tagged endogenous PC-1 (ref. 24) further conﬁrmed that
both uncleaved and cleaved PC-1 are sensitive to rapamycin
treatment (Fig. 4a). Interestingly, treatment in the presence of
cycloheximide, even for short periods of time (3 and 5 h)
prevented the rapamycin effect on PC-1 expression levels in these
cells as well, in line with the idea that protein neo-synthesis is
essential (Fig. 4a). Importantly, treatment with endoH revealed
that the endoH-resistant, mature form of PC-1 is downregulated
in Tsc1 / cells and is also sensitive to rapamycin treatment
(Fig. 4b and Supplementary Fig. 4a,b). Since recent work33–35 has
shown that this is the isoform of PC-1 which trafﬁcs to cilia and is
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likely essential for preventing renal cystogenesis, at least
postnatally, our data implicate that mTORC1 can affect the
expression levels of the functionally active form of PC-1 (ref. 33).
This is also the isoform of PC-1 which allows trafﬁcking of the
PC-1/PC-2 complex to primary cilia33. Of interest, PC-2
expression levels are not sensitive to rapamycin treatment
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Figure 4 | Protein neosynthesis is required for mTORC1 effect on PC-1 expression levels. (a) Western blot analysis with an anti-Myc antibody of Pkd1Myc/
Myc MEFs in the presence of cycloheximide shows that this prevents the capability of rapamycin (100nM) to upregulate PC-1 levels. (b) Immunoblot detecting
PC1 (rCC and LRR antibody) in MEFs treated with PNGaseF or EndoH. FL, full-length; NTF, N-terminal fragment; (R), EndoH-resistant; (S), EndoH-sensitive;
CTF, C-terminal fragment. (c) Western blot detecting PC1 (LRR) and PC2 in Tsc1þ /þ and Tsc1 /MEFs treated in the presence or absence of 100 nM
rapamycin. (d) Immunoﬂuorescence staining of PC2 (red, arrows) and primary cilia (acetylated tubulin, green, arrows) performed in Tsc1þ /þ and
Tsc1 /MEFs in the presence or absence of 100nM rapamycin for 24h. Scale bar, 10mm (high magniﬁcation) and 40mm (low magniﬁcation). Data are
representative of three independent experiments. (e) Graph showing the quantiﬁcation of the percentage of cilia per cell in Tsc1þ /þ and Tsc1 /MEFs,
before and after 100nM rapamycin for 24h. Cells counted: Tsc1þ /þ n¼ 281, Tsc1 / n¼437, Tsc1þ /þ Rapa. n¼ 166, Tsc1 / Rapa. n¼ 304. Data are
shown as mean±s.d. and are representative of three independent experiments. ANOVA statistical analysis (***Po0.0001) followed by Bonferroni’s multiple
comparison (compare selected pairs of columns) test was performed. NS, non signiﬁcant. (f) Graph shows quantiﬁcation of the percentage of PC2 positive
cilia in in Tsc1þ /þ and Tsc1 /MEFs ( number of cilia shown in e) before and after rapamycin treatment (100nM for 24h). Data are shown as mean±s.d.
and are representative of three independent experiments. ANOVA statistical analysis (***P¼0.0007) followed by Bonferroni’s multiple comparison test
(compare selected pairs of columns) was performed. NS, non signiﬁcant; **Po0.01. ANOVA, analysis of variance.
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(Fig. 4c). Therefore, we used staining of PC-2 as a read-out to test
the effect of mTORC1 on the capability of the PC-1/PC-2
complex to reach the primary cilium. We found that Tsc1 /
cells have a reduced number of cilia which stain positive to PC-2
as compared to controls (Fig. 4d,f), even if they appear to have a
slightly increased total number of cilia (Fig. 4e). Importantly,
treatment in the presence of rapamycin, signiﬁcantly increased
the percentage of PC-2 positive cilia in Tsc1 / cells (Fig. 4f).
Given that the total levels of the protein are unaffected (Fig. 4c),
our data indicate that rapamycin quantitatively increases the
amount of the PC-1/2 complex able to trafﬁc to cilia.
PC-1 downregulation mediates cystogenesis in Tsc1 mutants.
Based on this we wondered if downregulation of PC-1 might be
relevant in the context of the renal cystic phenotype observed in
the Tsc1ﬂox/ﬂox:KspCre mice. We reasoned that if downregulation
of PC-1 is involved in cyst formation, lowering the starting
amount of PC-1 might enhance the phenotype in Tsc1 mutants.
To test this, we inter-crossed Tsc1ﬂox/ﬂox:KspCre with Pkd1þ /
mice, which do not manifest any cystic phenotype (Fig. 5a).
Indeed, the resulting Tsc1ﬂox/ﬂox:Pkd1þ / :KspCre double
mutants have a more aggressive renal cystic phenotype as
compared with Tsc1ﬂox/ﬂox:KspCre mice (Fig. 5a). While the
kidney/body weight did not change (Fig. 5b), the cystic index
in the double mutants highlights a very signiﬁcant increase
in cystogenesis (Fig. 5c and Supplementary Fig. 5a–d),
suggesting that the starting amount of PC-1 in these kidneys is a
critical modiﬁer of disease progression in the Tsc1 mutants. Based
on these data we hypothesized that downregulation of PC-1 in
Tsc1 mutants is an important driver of cyst formation. To
formally test this hypothesis, we inter-crossed Tsc1ﬂox/ﬂox:KspCre
mice with a murine line overexpressing three copies of a
Pkd1-BAC clone (Pkd1F/H transgenic line, Tg248)36.
Overexpression of Pkd1 indeed resulted in a much milder and
delayed cystic phenotype (Fig. 5d) reduced kidney/body weight
(Fig. 5e), a correction of the cystic index (Fig. 5f and
Supplementary Fig. 6a) and an improved renal function
(Fig. 5g). Of great interest, the Pkd1 gene was not able to
correct the columnar phenotype of the epithelium lining the cysts
in Tsc1 mutants, suggesting that additional factors must be
altered in these epithelia and account for the different
morphology (Supplementary Fig. 1g), in line with the fact that
these mice eventually manifest cancerous lesions unlike the Pkd1
mutants (unpublished data from L.D., M.P. and A.B.). A previous
study has shown that inactivation of the Pkd1 gene before P13 in
the mouse results in an aggressive model of cystogenesis, whereas
inactivation after P13 results in a much slower renal cystic
phenotype37. Since our data demonstrate that cystogenesis in the
Tsc1ﬂox/ﬂox:KspCre mice is inﬂuenced by the expression levels of
PC-1, we reasoned that treatment of Tsc1 mutant mice with
rapamycin for a short period of time just to cover the critical
window of time which determines the timing of a cystic
manifestation in response to Pkd1 inactivation should result in
long-lasting beneﬁcial effects on renal cystogenesis. Indeed, we
treated Tsc1ﬂox/ﬂox:KspCre for a short time (P8–P20) followed by
a release of the treatment for a longer time (P20–P50) and found
that treatment for only 12 days to overcome the critical time
point of P13 results in a very profound reversion of the renal
cystic phenotype in these animals at P50 (Fig. 5h–j and
Supplementary Fig. 6b) and improved renal function (Fig. 5k).
Importantly, we used a mouse model carrying endogenous tagged
PC-1 (Pkd1HA) (ref. 24) and found that treatment with
rapamycin leads to enhanced expression of PC-1 in the kidney,
further conﬁrming that mTORC1 regulates PC-1 expression
levels in vivo (Fig. 5l).
Discussion
We conclude that downregulation of PC-1 plays a key role in the
cystogenesis observed in Tsc1 mutants. In addition, given
the different phenotype observed in the Pkd1 and Tsc1 mutant
kidneys our data show that likely PC-1 protection from
cystogenesis is mediated through mTORC1-independent
mechanisms (Fig. 6). However, mTORC1 upregulation in
response to Pkd1 inactivation likely contributes to increased
proliferation, justifying the beneﬁcial effects observed upon
treatment with rapamycin in several PKD models8.
PC-1 expression levels are ﬁnely regulated and its
downregulation below a critical threshold of expression or
activity causes cyst formation in humans and mice35,38–40. In
the model proposed in this study PC-1 inhibits mTORC1, which
in turn downregulates PC-1 levels, in a feedback loop, which is
ultimately acting as a positive feedback on mTORC1 activity
(Fig. 6). Our data contribute to explaining the renal cystic
phenotype observed upon inactivation of Tsc genes in the
kidney, but more importantly they potentially explain the severe
cystic phenotype observed in individuals affected by the TSC/PKD
contiguous genes syndrome19. In this case, each gene is halved
and any perturbation of the system causing a minimal drop of
activity in one or the other of the two gene products would
result in a self-perpetuating circle causing progressive
upregulation of mTORC1 and downregulation of PC-1 (Fig. 6).
Importantly, our data suggest that rapamycin or other mTOR
inhibitors might be more effective in these patients, or in any
renal cystic disease in which some level of activity of the PKD1
gene is maintained39,41. The severe cases of ADPKD (carrying
truncating mutations) might not be sensitive to rescue through
the mechanism proposed here41.
One implication of our results is that it might be interesting to
revisit some of the studies generated by the use of everolimus or
sirolimus in clinical trials16,17, by stratifying the treated patients
on the basis of their inherited genetic germline mutation. In fact,
a landmark study has shown that there is a genotype–phenotype
correlation when analysing the renal outcome in patients carrying
PKD1 mutations: those individuals carrying germline missense
mutations have a better outcome than those individuals carrying
truncating mutations41. These results suggest that the PKD1
missense variants retain some of their function. Further to this,
previous studies have shown that occasionally individuals can
carry hypomorphic mutations in the PKD1 gene, which do not
cause any or a very mild renal manifestation when carried in
heterozygosity, but show a marked renal cystic phenotype when
carried in homozygosity39. These data strongly suggest that the
type of mutation carried by the PKD1 gene can cause a graded
effect on the polycystin-1 protein function that can range from
very mild to very severe. Based on our proposed model we would
predict that individuals carrying a missense or a hypomorphic
mutation should be more sensitive to the treatment with any
analogue of rapamycin because upregulation of a PC-1 protein
with reduced function might be sufﬁcient to bring the level of
activity above threshold, thus correcting cystogenesis.
Importantly, our study suggests that discontinuation of the
drug might apply in all these cases, possibly reducing any side
effect.
Further to this, previous studies have suggested that PC-1
downregulation is central to the renal cystic phenotype in
ARPKD36,42. Chaperones able to facilitate PC-1 trafﬁcking
might be one possible approach to restore its function43.
Based on our data, we would predict that rapamycin or any
inhibitor of mTORC1 may act through the mechanism proposed
in this study and be effective in ARPKD as well. Obviously it
would not be conceivable to administer any of the current
compounds inhibiting mTOR in infants or during pregnancy
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and the short-term implications of our studies for this
speciﬁc disease are certainly less immediate. However, if
humans are sensitive to a critical developmental window of
PC-1 expression similar to what has been observed in mice37,
one could think to achieve a long-term beneﬁcial effect in
this devastating human condition by correcting PC-1 expression
levels during the fetal or neonatal life. Our study shows that
the regulation of PC-1 by mTORC1 occurs at the
post-transcriptional level and likely at the protein synthesis
level. It will be essential to further characterize the molecular
mechanism underlying this regulation and to identify the key
molecules involved. This might further open therapeutical
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Figure 5 | Downregulation of PC-1 in Tsc1 mutant kidneys contributes to cyst formation. (a) H&E staining of kidney sections from Tsc1f/f:KspCre, Tsc1f/
f:Pkd1þ /-:KspCre and control mice at P20. Scale bar, 1,000mm. (b) Graph shows the two kidneys over body weight ratio at P20 in Tsc1f/f:KspCre (n¼ 9) and
Tsc1f/f:Pkd1þ /-:KspCre (n¼ 13) compared with controls (n¼ 18). Data are shown as mean±s.e.m. (c) Graph shows the cystic index in Tsc1f/f:KspCre (n¼ 9)
compared to Tsc1f/f: KspCre:Pkd1þ / (n¼ 13) mice at P20. Data are shown as mean±s.e.m. (d) H&E staining performed in P30 kidney sections from
controls, Tsc1f/f:KspCre and Tsc1f/f: KspCre:Pkd1-BAC transgenic mice (n¼ 5). Scale bar, 1,000 mm. (e) Graph shows the two kidneys over body weight ratio in
controls (n¼ 15), Tsc1f/f:KspCre (n¼ 12) and Tsc1f/f:Pkd1-BAC:KspCre (n¼9) transgenic mice. Data are shown as mean±s.e.m. (f) Cystic index analysis in
kidneys at P30 of Tsc1f/f: KspCre:Pkd1-BAC transgenic mice (n¼ 9) compared to Tsc1f/f:KspCre (n¼ 9). Data are shown as mean±s.e.m. (g) Graph shows
analysis of BUN at P30 in mice from ﬁgure (e) Data are shown as mean±s.e.m. (h) H&E staining on kidney sections from untreated or rapamycin
(1mg kg 1) treated Tsc1f/f:KspCre mice at P50. In green are shown the untreated Tsc1f/f:KspCre mice. Scale bar, 1,000mm. (i) Graph shows the two kidneys
weight over body weight ratio at P50 in controls (n¼ 12) and Tsc1f/f:KspCremice untreated (n¼ 20) and after rapamycin treatment (n¼ 5). (j) Graph shows
the cystic index of one of two kidneys derived from mice treated in (h). Data are shown as mean±s.e.m. (k) Graph shows analysis of BUN at P50 in
controls and Tsc1f/f:KspCre untreated (control n¼ 19, cystic n¼ 10) or treated with rapamycin (control n¼4, cystic n¼9). Data are shown as mean±s.e.m.
(l) Immunoprecipitation of endogenous HA-PC-1 from P8 kidneys of Pkd1HA/HAmice, treated or not with 1mg kg 1 rapamycin, followed by a western blot
with anti-HA (FL, Full-length PC-1; CTF, C-terminal cleavage) or anti-LRR antibodies Data are representative of two independent experiments. ANOVA
statistical analysis followed by Bonferroni’s multiple comparison test was performed in b,e,g,i,k. Student’s unpaired two-tailed t-test statistical analysis was
performed in c,f,j. *Po0.05; **Po0.01;***Po0.001; ****Po0.0001; NS, non signiﬁcant. ANOVA, analysis of variance.
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opportunities allowing to achieve PC-1 upregulation without
administration of rapalogues.
In sum, our data uncover a novel, unanticipated reciprocal
regulation of PC-1 and mTORC1, which revisits the role of
mTORC1 in renal cystogenesis, opening new perspectives for
therapy.
Methods
Antibodies and inhibitors. For western blot analysis we used antibodies against
pP70S6K Thr389 (#9205 1:1,000), pP70S6K Thr421/Ser424 (#9204 1:1,000), pS6Rp
Ser235/236 (#2211 1:5,000), pS6Rp Ser240/244 (#2215 1:10,000), S6RP (# 2217
1:1,000), TSC1 (#4906 1:1,000), b-Catenin (#9562 1:1,000) and Myc-Tag (#2272)
obtained from Cell Signaling Technology. HA antibody (#11867423001, 1:500) was
from Roche. P70S6K C-18 (#sc-230 1:1,000), PC1-LRR 7E12 (#sc-130554 1:1,000),
PC2 D3 (#sc-28331 1:500), Ubiquitin P4D1 (#sc-8017 1:10,000) and DAPI
(# sc- 3598 1:5,000) were from Santa Cruz Biotechnology. The rat monoclonal
antibody (rCC) against the C-terminal tail of mouse PC1 was described in
Kurbegovic et al.30 Antibodies to detect LC3 NB100 (#2331 1:500) from Novus
Biologicals, b-actin (#A5441 1:25,000) and a-tubulin (#T5168 1:25,000) from
Sigma Aldrich, Vinculin V284 (#05-386 1:15,000) was obtained from Millipore.
Horseradish peroxidase (HRP)-conjugated secondary antibodies were from GE
Healthcare, anti-rabbit HRP linked (# NA934V) and anti-mouse HRP linked
(# NXA931). For immunoﬂuorescence staining LTL (Fluorescin Lotus Lectin)
#FL-1321 and DBA (Rhodamine Dolichos Biﬂorus Agglutinin) #RL-1032 were
obtained from Vector Laboratories and used 1:100, Acetyl-a-Tubulin (Lys40)
(D20G3) (#5335) was from Cell Signaling Technology and used 1:1,000. For
immunohistochemistry we used the Ki67 antibody (NCL-Ki67p) concentrated
1:200 and obtained from Novocastra.
Rapamycin was obtained from LC Laboratories (#R-5000) dissolved in DMSO
and used at a ﬁnal concentration of 100 nM (or other) for cell treatment.
Bortezomib (#B1408) from LC Laboratories was dissolved in DMSO and used at a
ﬁnal concentration of 25, 50 and 75Nm for 16 h. Chloroquine (#C-6628, Sigma)
was dissolved in water and used for 18 h at 25, 50 and 100 mM ﬁnal concentration.
Cycloheximide (#C-7698, Sigma) dissolved in ethanol and used at 50 mM
concentration. Baﬁlomycin A1 (#B1793) was obtained from Sigma, dissolved in
DMSO and used at a ﬁnal concentration of 50Nm. Torin 1 (#4247) was obtained
from Tocris, dissolved in DMSO and used 300 nM.
Cell Cultures and treatments. For rapamycin treatment MEFs9, MDCK and
mIMCD epithelial cells31 were cultured sub-conﬂuent in DMEM (Gibco) supplied
with 10% serum (Euroclone) and 1% Pen/Strep (Gibco). Before treatment cells
were serum starved overnight using DMEM supplied with 0.4% serum, 1% Pen/
Strep. For bortezomib, chloroquine and cycloheximide treatment MEFs were plated
at high conﬂuence.
For the glycosylation assay we used New England Biolabs’ enzymes according to
their instruction. Cell lysates were denatured using glycoprotein denature buffer for
1min at 95 C and then quickly chilled on ice. The denatured glycoprotein was
incubated with PNGaseF or EndoH for 1 h at 37 C (ref. 33).
Generation of Tsc1-silenced mIMCD cells. Pre-screening of shRNAs targeting
murine Tsc1 was performed as follows: 500,000 mIMCD cells were seeded and 24 h
later transduced with viral vectors expressing shRNA encoding scrambled (shScr)
sequences (MISSION TRC2 Control Transduction Particle puro Non-Target
shRNA 4,1 107 TUml 1 SHC202V from SIGMA) or six different Tsc1-targeting
shRNAs sequences (shTSC1 A-F, MiSSION Lentiviral Transduction Particles
SHCLNV from SIGMA, batch A TRCN0000113949 1,8 107 TUml 1,
batch B TRCN0000238186 2,0 107 TUml 1, batch C TRCN0000238187
2,0 107 TUml 1, batch D TRCN0000238188 1,5 107 TUml 1, batch E
TRCN0000238189 1,5 107 TUml 1 and batch F TRCN0000244252 1,6
107 TUml 1) using multiplicity of infection 1 and 2. 48 h after transduction cells
were collected, lysed and analysed by SDS–polyacrylamide gel followed by western
blot analysis using anti-TSC1, anti-pP70T389, anti-pS6RpS235-236 and anti-a tubulin
antibodies.
For stable transduction, 500,000 mIMCD cells were seeded into six-well plates
and grown in DMEM (Invitrogen), supplemented with 10% v/v fetal bovine serum
and 1:100 penicillin 5,000Uml 1 per 5000 mgml 1 streptomycin solution
(Invitrogen). mIMCD cells were transduced with viral vectors expressing shRNA
encoding scrambled sequences (shScr) or the selected Tsc1-targeting shRNA
sequence (shTSC1) under puromycin selection, using MOI 2. 48 h after
transduction, cells were splitted and medium containing 1 mgml 1 puromycin
(Invitrogen) was added. Untransduced cells were treated with the same puromycin
concentration to establish the maximal toxicity of puromycin. After 6 days no
untransduced cells survived, and selection of puromycin-resistant clones was
concluded. Clones were collected as pools containing several different selected
clones. Resistant cells were analysed for Tsc1 expression levels as above. Next,
resistant clones were sub-cloned by limiting dilutions and 20 sub-clones selected
for shTSC1C, 14 clones for shTSC1F and 10 clones for shScr. At conﬂuency cells
were analysed for Tsc1 and mTORC1 pathway-related protein (pP70 and pS6Rp)
expression levels and phosphorylation. Two clones carrying high silencing levels
(F5 and F8) and two control clones (Sc4 and Sc8) were selected for further use.
Generation of Pkd1 and Tsc1 mice. To generate Pkd1f/ :KspCre mice we crossed
Pkd1f/f(ref. 24) and Pkd1þ / :KspCre mice. To generate Tsc1f/f:KspCre and Pkd1f/f:
KspCre mice we inter-crossed Tsc1f/þ :KspCre and Pkd1f/þ :KspCre mice,
respectively. To generate Tsc11f/ :KspCre mice we crossed Tsc1f/f and Tsc1f/-:
KspCre mice that were in a mixed genetic background (fourth generation of
backcrosses in C57BL6 pure genetic background). To generate Tsc1f/f:Pkd1-
BAC:KspCre mice we crossed Tsc1f/þ :KspCre with Tsc1f/þ : Pkd1-BAC: KspCre.
Pkd1-BAC (Tg.248) were described elsewhere36. All the mice used in these
experiments were in pure C57BL6 genetic background (backcrossed over nine
times). Animals used were half males and half females. For rapamycin
(LC Laboratories) treatments, we intraperitoneally injected rapamycin in DMSO in
NaCl or vehicle alone daily to the mothers from P2/3 until P10 at 1mg per kg body
weight. Starting from P10 we start treating directly the pups by intraperitoneal
injections of rapamycin at 1mg per kg body weight or vehicle alone. All animal
care and experimental protocols were conducted after approval of a speciﬁc
protocol (IACUC-548) by the institutional care and use ethical committee at the
San Raffaele Scientiﬁc Institute.
Histology, immunoﬂuorescence and immunohistochemistry. For histological
analysis mice were sacriﬁced at the given time point, kidneys were collected,
weighted and ﬁxed in 4% Paraformaldehyde over night at 4 C. For rapamycin
treated mice, before collecting kidneys, mice were anaesthetized and perfused in PBS.
Fixed kidneys were processed through a sucrose (Sigma) gradient in PBS from 10 to
30%, treated with 10% glycerol, 30%sucrose, PBS and ﬁnally embedded in Killik
(Bio Optica) for frozen sections. Kidney sections were air dried, rehydrated in PBS,
stained for 2min in 1:10 Harris Hematoxylin (Sigma), washed in abundant water,
stained 30 s in eosin G (Bio Optica) and washed again. After staining, kidney sections
were dehydrated through an alcohol gradient and then mounted in DPX (Sigma).
For immunoﬂuorescence staining of DBA and LTL positive tubules 14 mm
kidney sections were washed in PBS, ﬁxed 10min in 4% paraformaldehyde and
permeabilized in 0,1% Triton x-100,PBS. We blocked sections in 5% Normal Goat
serum (Sigma), 3% BSA, PBS for 1 h room temperature, incubated overnight at
4 C with primary antibodies diluted in blocking solution as described, washed with
PBS, the nucleus was stained with DAPI and mounted with mowiol (Sigma).
Images were obtained using UltraView spinning disk confocal microscope
(PerkinElmer) with a Plan Apochromat 63X/1.4 oil immersion or a  20 objective
using the UltraVier ERS acquisition software.
For immunohistochemistry of Ki67 positive cells, frozen kidney sections were
air dried and washed in PBS. Endogenous peroxide was blocked for 10min with
0.5% v.v. hydrogen peroxide in MetOH. For antigen unmasking sections were
boiled in 10mM citrate buffer Ph 6.0. Primary antibody was incubated O/N in 3%
BSA, 5% NGS in PBS. The secondary antibody and the DABþ developing solution
were from Dako (K3468). H&E staining was used to vizualize nuclei, sections were
dehydrated and mounted in DPX.
Cystic index analysis. To quantify the number of cysts, we obtained longitudinal
sections from the inner part of the kidney, performed H&E staining and then get
 4 images (Nikon Eclipse E600 microscope, Nikon Digital Camera DXM1200,
ACT-1 software) for each kidney section. We used Image J programme
(http://rsb.info.nih.gov/ij/) to quantify the surface, expressed in pixels, covered by
cysts in each kidney. We used a cutoff of 2,000 pixels as the minimum surface that
a cyst should have to be included in the analysis. We next calculated the ratio
between the obtained cystic area and the area of the entire kidney section and
expressed it as the percentage of cysts for the given kidney.
Real-time PCR analysis. We isolated total RNA from plated cells using the
RNAspin Mini kit (GE Healthcare). Total RNA from kidneys was isolated using the
PC-1
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Cysts
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mTORC1
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Figure 6 | Proposed model of cross regulation of the PKD and TSC
genes. Schematic summary of the proposed model. PC-1 inhibits the
mTORC1 pathway by acting on the TSC genes (previous work3,4),
whereas mTORC1 acts in a negative feedback loop to downregulate
PC-1 expression levels.
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RNA-Isol Lysis reagent (5 Prime) according to the manufacturer’s instructions. We
obtained cDNA from using Oligo(dt)12-18 primers (#18418012) and Superscript II
Reverse Transcriptase (#18064014) from Life Technologies. For reverse
transcription of RNA extracted from kidneys, we used Oligo(dt)15 primers
(#C110B) and ImProm-II Reverse Transcriptase (#A3802) from Promega. We
performed quantitave real-time PCR analysis on duplicate using SYBR Green I
master mix (#04707516001,Roche) on LightCycler 480 Instrument (Roche).
We used the following primers for qRT-PCR: Pkd1 FW 50-GGCGGCTTTGTG
ATTTGTAT-30 , Pkd1 RV 30-ACCTGAATCGGGGGATAAAC-50 , Beta actin FW
50-AGAAAATCTGGCACCACACC-30, Beta actin RV 30-CAGAGGCGTACAG
GGATAGC-50 . Arbp FW 50- CTTCATTGTGGGAGCAGACA-30 and Arbp RV
30- TTCTCCAGAGCTGGGTTGTT-50 .
Western blot analysis. For western blot analysis cells or kidneys were lysed in
lysis buffer solution of 150mM NaCl, 20mM Na4HPO4/NaH2PO4, 10% glycerol,
1% Triton X-100 ( pH 7.2), complete protease inhibitors (Roche) and phosphatase
inhibitors (1mM ﬁnal concentration of glycerophosphate, sodium orthovanadate
and sodium ﬂuoride). Total lysates were then quantiﬁed with Biorad Protein Assay
(Biorad) and Laemmli buffer at a ﬁnal concentration  2 was added to the
samples. Proteins were next resolved in 3–8% Tris-Acetate gels (Life Technologies)
and then transferred onto polyvinylidene ﬂuoride membranes (Millipore). We then
blocked membranes with 5% milk in Tris-buffered saline, Tween 20 (TBS-T).
All the primary antibodies for western blot analysis were diluted in 3% BSA
(#A7906, Sigma), TBS-T. HRP-conjugated secondary antibodies were diluted
1:10,000 (or more if necessary) in 5% milk, TBS-T and detection was made with
ECL (#RPN2106, GE) alone or supplied with 10% SuperSignal West Femto
(#34095,Thermo Scientiﬁc) when necessary.
Immunoprecipitation studies. To immunopecipitate PC-1 HA, P8 kidneys were
collected from a mouse model carrying endogenous HA tagged PC-1 (Pkd1HA)24,
treated or not treated with 1mg kg 1 rapamycin from P4 to P8. Kidneys were
lysed in lysis buffer solution with 1% Triton X-100 and equal amounts of total
lysates were incubated over night at 4 C in rocking conditions with anti-HA-high
afﬁnity matrix (Roche). After several washes with lysis buffer, beads were
resuspended in loading laemmli buffer and proteins resolved in 3–8% Tris-acetate
gradient gels.
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